The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.

Case Study: Mayo Clinic Study Uses IBL-America's Amyloid Beta

Oct 15th 2021

Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-β42 in Alzheimer’s disease

Accumulation of amyloid-β peptides is a dominant feature in the pathogenesis of Alzheimer’s disease; however, it is not clear how individual amyloid-β species accumulate and affect other neuropathological and clinical features in the disease. 

Thus, we compared the accumulation of N-terminally truncated amyloid-β and full-length amyloid-β, depending on disease stage as well as brain area, and determined how these amyloid-β species respectively correlate with clinicopathological features of Alzheimer’s disease. 

To this end, the amounts of amyloid-β species and other proteins related to amyloid-β metabolism or Alzheimer’s disease were quantified by enzyme-linked immunosorbent assays (ELISA)...Read more

Learn more about our Amyloid Beta 1-40 and 1-42 (FL) assays:

Amyloid Beta ( 1-40 ) ( FL ) Aβ

Amyloid Beta ( 1-42 ) ( FL ) Aβ


View ALL Amyloid Beta

OUR ASSAY KIT CATEGORIES